Indaptus Therapeutics to Present at Two Upcoming Investor Conferences
Indaptus Therapeutics (Nasdaq: INDP) has announced its participation in two upcoming investor conferences in New York City. CEO Jeffrey A. Meckler will present at BioFuture 2024 on October 28 at 3:30 PM ET at Cure by Deerfield, and at the ThinkEquity Conference on October 30 at 12:30 PM ET at the Mandarin Oriental Hotel. Meckler will be available for one-on-one meetings during both conferences. Interested investors can register to attend and schedule meetings through the provided links.
Indaptus Therapeutics (Nasdaq: INDP) ha annunciato la sua partecipazione a due prossime conferenze per investitori a New York City. Il CEO Jeffrey A. Meckler presenterà a BioFuture 2024 il 28 ottobre alle 15:30 ET presso Cure by Deerfield, e alla ThinkEquity Conference il 30 ottobre alle 12:30 ET al Mandarin Oriental Hotel. Meckler sarà disponibile per incontri one-to-one durante entrambe le conferenze. Gli investitori interessati possono registrarsi per partecipare e pianificare incontri attraverso i link forniti.
Indaptus Therapeutics (Nasdaq: INDP) ha anunciado su participación en dos próximas conferencias para inversores en la ciudad de Nueva York. El CEO Jeffrey A. Meckler presentará en BioFuture 2024 el 28 de octubre a las 3:30 PM ET en Cure by Deerfield, y en la ThinkEquity Conference el 30 de octubre a las 12:30 PM ET en el Hotel Mandarin Oriental. Meckler estará disponible para reuniones individuales durante ambas conferencias. Los inversores interesados pueden registrarse para asistir y programar reuniones a través de los enlaces proporcionados.
Indaptus Therapeutics (Nasdaq: INDP)는 뉴욕시에서 열리는 두 개의 투자자 회의에 참가한다고 발표했습니다. CEO 제프리 A. 멕클러는 10월 28일 오후 3시 30분 ET에 Cure by Deerfield에서 열리는 BioFuture 2024에서 발표할 예정이며, 10월 30일 오후 12시 30분 ET에 만다린 오리엔탈 호텔에서 열리는 ThinkEquity Conference에도 참석합니다. 멕클러는 두 회의 동안 일대일 미팅을 위해 자리를 마련할 것입니다. 관심 있는 투자자는 제공된 링크를 통해 참석 등록 및 미팅 일정을 조정할 수 있습니다.
Indaptus Therapeutics (Nasdaq: INDP) a annoncé sa participation à deux conférences pour investisseurs à venir à New York City. Le PDG Jeffrey A. Meckler présentera à BioFuture 2024 le 28 octobre à 15h30 ET chez Cure by Deerfield, et à la ThinkEquity Conference le 30 octobre à 12h30 ET à l'hôtel Mandarin Oriental. Meckler sera disponible pour des réunions individuelles durant les deux conférences. Les investisseurs intéressés peuvent s'inscrire pour assister et planifier des réunions via les liens fournis.
Indaptus Therapeutics (Nasdaq: INDP) hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen in New York City angekündigt. CEO Jeffrey A. Meckler wird am 28. Oktober um 15:30 Uhr ET bei BioFuture 2024 in Cure by Deerfield sprechen und am 30. Oktober um 12:30 Uhr ET bei der ThinkEquity Conference im Mandarin Oriental Hotel. Meckler wird während beider Konferenzen für Einzelgespräche zur Verfügung stehen. Interessierte Investoren können sich über die bereitgestellten Links zur Teilnahme anmelden und Meetings planen.
- None.
- None.
NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present at two upcoming investor conferences:
BioFuture 2024
The conference is being held on October 28 – 30, 2024 at Cure by Deerfield in New York City.
Presentation Date: | Monday, October 28, 2024 |
Time: | 3:30 PM ET |
Track: | 12 - B (12th Floor) |
Mr. Meckler will be available for one-on-one meetings throughout the conference.
For more information about BioFuture, click here: https://biofuture.com/
ThinkEquity Conference
The conference is being held on October 30, 2024 at the Mandarin Oriental Hotel in New York City.
Presentation Date: | Wednesday, October 30, 2024 |
Time: | 12:30 PM ET (South Salon II) |
Mr. Meckler will be available for one-on-one meetings throughout the conference.
Interested investors can register to attend and schedule one-on-one meetings here.
About Indaptus Therapeutics
Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The product candidates are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy product candidates represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas, pancreatic and non-Hodgkin’s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts. In pre-clinical studies tumor eradication was observed with Decoy product candidates in combination with anti-PD-1 checkpoint therapy, low-dose chemotherapy, a non-steroidal anti-inflammatory drug, or an approved, targeted antibody. Combination-based tumor eradication in pre-clinical models produced innate and adaptive immunological memory, involved activation of both innate and adaptive immune cells, and was associated with induction of innate and adaptive immune pathways in tumors after only one i.v. dose of Decoy product candidate, with associated “cold” to “hot” tumor inflammation signature transition. IND-enabling, nonclinical toxicology studies demonstrated i.v. administration without sustained induction of hallmark biomarkers of cytokine release syndromes, possibly due to passive targeting to liver, spleen, and tumor, followed by rapid elimination of the product candidate. Indaptus’ Decoy product candidates have also produced meaningful single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These include statements regarding management’s expectations, beliefs and intentions regarding, among other things: our expectations and plans regarding our Phase 1 clinical trial of Decoy20, including the timing and design thereof and expected immune responses as we dose more patients in the multi-dosing part of the trial; the anticipated effects of our product candidates, including Decoy20; the plans and objectives of management for future operations; our research and development activities and costs; the sufficiency of our cash and cash equivalents to fund our ongoing activities and our cash management strategy; and our assessment of financing options to support our corporate strategy. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to the following: our limited operating history; conditions and events that raise substantial doubt regarding our ability to continue as going concern; the need for, and our ability to raise, additional capital given our lack of current cash flow; our clinical and preclinical development, which involves a lengthy and expensive process with an uncertain outcome; our incurrence of significant research and development expenses and other operating expenses, which may make it difficult for us to attain profitability; our pursuit of a limited number of research programs, product candidates and specific indications and failure to capitalize on product candidates or indications that may be more profitable or have a greater likelihood of success; our ability to obtain and maintain regulatory approval of any product candidate; the market acceptance of our product candidates; our reliance on third parties to conduct our preclinical studies and clinical trials and perform other tasks; our reliance on third parties for the manufacture of our product candidates during clinical development; our ability to successfully commercialize Decoy20 or any future product candidates; our ability to obtain or maintain coverage and adequate reimbursement for our products; the impact of legislation and healthcare reform measures on our ability to obtain marketing approval for and commercialize Decoy20 and any future product candidates; product candidates of our competitors that may be approved faster, marketed more effectively, and better tolerated than our product candidates; our ability to adequately protect our proprietary or licensed technology in the marketplace; the impact of, and costs of complying with healthcare laws and regulations, and our failure to comply with such laws and regulations; information technology system failures, cyberattacks or deficiencies in our cybersecurity; and unfavorable global economic conditions. These and other important factors discussed under the caption “Risk Factors” included in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the SEC on August 12, 2024, our most recent Annual Report on Form 10-K filed with the SEC on March 13, 2024, and our other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. We undertake no obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable law.
Contact: investors@indaptusrx.com
Investor Relations Contact:
CORE IR
Louie Toma
louie@coreir.com
Media Contact:
Cuttlefish Communications
Shira Derasmo
shira@cuttlefishpr.com
917-280-2497
FAQ
When will Indaptus Therapeutics (INDP) present at BioFuture 2024?
What time is Indaptus Therapeutics (INDP) presenting at the ThinkEquity Conference?
Can investors schedule one-on-one meetings with Indaptus Therapeutics (INDP) at these conferences?